triglycer

  1. T

    Spherix Phase 2 Trial With D-tagatose Determines Minimum Dose For HbA1c And Triglycer

    Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, announced that its Phase 2 diabetes...
Back
Top